John G. Clarkson, M.D. Joins Noven Board of Directors

-- Noven Pharmaceuticals, Inc. (Nasdaq:NOVN - news) today announced the appointment of John G. Clarkson, M.D. to its board of directors.

Dr. Clarkson is Senior Vice President for Medical Affairs and Dean of the University of Miami School of Medicine. During his university career, he has also served as Chairman of the Department of Ophthalmology/Bascom Palmer Eye Institute at the University of Miami School of Medicine; Medical Director at Anne Bates Leach Eye Hospital; and Associate Vice President for Medical Affairs and Medical Director for Clinical Practice for the University of Miami Medical Group. He continues as Professor of Ophthalmology, Department of Ophthalmology/Bascom Palmer Eye Institute, University of Miami School of Medicine.

During a distinguished medical, research and academic career spanning over 30 years, Dr. Clarkson has served as principal investigator in significant research projects funded by the National Eye Institute and the National Heart, Lung and Blood Institute of the National Institutes of Health, and has authored or co-authored over 50 published works. He received his MD degree from the University of Miami School of Medicine and his BA degree from Princeton University.

``Dr. Clarkson is an important addition to our board of directors,'' said Robert Strauss, Noven's President and Chief Executive Officer. ``He brings broad medical, academic and clinical research experience to Noven that will prove invaluable as our 20 research and development projects move through clinical trials and into the market.''

Noven Pharmaceuticals, Inc., headquartered in Miami, Florida, is a leader in the development of transdermal and transmucosal drug delivery technologies and products. Together with Novartis Pharmaceuticals, Noven owns a highly profitable women's health products company called Novogyne Pharmaceuticals. Noven's existing products include advanced estrogen transdermal delivery systems (including Vivelle-Dot(TM), licensed to Novogyne); combination estrogen/progestin transdermal delivery systems (including CombiPatch(TM), licensed to Aventis S.A., and Estalis®, licensed to Novartis Pharma AG); and the first transmucosal patch delivery system approved by the FDA (DentiPatch®). With a range of additional products in development, including MethyPatch(TM) (transdermal methylphenidate system), Noven is committed to becoming the world's premier developer, manufacturer and marketer of transdermal and transmucosal drug delivery systems.

Forward looking statements contained in this release are qualified by and subject to the risks and uncertainties specified below and those specified by Noven in its most recent filings with the Securities and Exchange Commission, including the risks that Noven's NDA filing may be delayed, that Noven may not receive FDA approval to market MethyPatch™, that Noven may not successfully commercialize MethyPatch™, that MethyPatch™ may not compete effectively against extended release oral formulations of methylphenidate and/or other AD/HD medications, including those that may reach the U.S. market prior to MethyPatch™, and that Noven's patents may not provide meaningful protection against other patch products that may be developed by competitors.